New cancer drug enters first human safety trial
NCT ID NCT05105971
Summary
This was a first-in-human study to test the safety and find the right dose of a new drug called BAT6026 for patients with advanced solid tumors. It involved 30 adults whose cancer had progressed despite standard treatments. The main goal was to see how much of the drug patients could tolerate and to check for any serious side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.